BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8760309)

  • 41. Genes involved in melanoma: an overview of INK4a and other loci.
    Castellano M; Parmiani G
    Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations.
    Zhang S; Endo S; Koga H; Ichikawa T; Feng X; Onda K; Washiyama K; Kumanishi T
    Jpn J Cancer Res; 1996 Sep; 87(9):900-7. PubMed ID: 8878451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b).
    Malumbres M; Pérez De Castro I; Hernández MI; Jiménez M; Corral T; Pellicer A
    Mol Cell Biol; 2000 Apr; 20(8):2915-25. PubMed ID: 10733595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deletion of the p16 and p15 genes in human bladder tumors.
    Orlow I; Lacombe L; Hannon GJ; Serrano M; Pellicer I; Dalbagni G; Reuter VE; Zhang ZF; Beach D; Cordon-Cardo C
    J Natl Cancer Inst; 1995 Oct; 87(20):1524-9. PubMed ID: 7563186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo.
    Huang ZY; Baldwin RL; Hedrick NM; Gutmann DH
    Oncogene; 2002 Feb; 21(9):1325-34. PubMed ID: 11857076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic profile of gliosarcomas.
    Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
    Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
    Ng MH; Chung YF; Lo KW; Wickham NW; Lee JC; Huang DP
    Blood; 1997 Apr; 89(7):2500-6. PubMed ID: 9116295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deletions and point mutations of p16,p15 gene in primary tumors and tumor cell lines.
    Yonghao T; Qian H; Chuanyuan L; Yandell DW
    Chin Med Sci J; 1999 Dec; 14(4):200-5. PubMed ID: 12894891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alteration of p16 and p15 genes in common epithelial ovarian tumors.
    Fujita M; Enomoto T; Haba T; Nakashima R; Sasaki M; Yoshino K; Wada H; Buzard GS; Matsuzaki N; Wakasa K; Murata Y
    Int J Cancer; 1997 Apr; 74(2):148-55. PubMed ID: 9133447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of the tumour suppressor genes p15 and p16 in malignant melanoma.
    Robinson WA; Elefanty AG; Hersey P
    Melanoma Res; 1996 Aug; 6(4):285-9. PubMed ID: 8873047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
    Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
    J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Establishment and partial characterization of five malignant glioma cell lines.
    Zhang L; Yamane T; Satoh E; Amagasaki K; Kawataki T; Asahara T; Furuya K; Nukui H; Naganuma H
    Neuropathology; 2005 Jun; 25(2):136-43. PubMed ID: 15875906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors.
    Naumann M; Savitskaia N; Eilert C; Schramm A; Kalthoff H; Schmiegel W
    Gastroenterology; 1996 Apr; 110(4):1215-24. PubMed ID: 8613012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues.
    Izumoto S; Arita N; Ohnishi T; Hiraga S; Taki T; Hayakawa T
    Cancer Lett; 1995 Nov; 97(2):241-7. PubMed ID: 7497469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
    Matsumura Y; Nishigori C; Yagi T; Imamura S; Takebe H
    Arch Dermatol Res; 1998 Apr; 290(4):175-80. PubMed ID: 9617435
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb.
    Grønbaek K; Nedergaard T; Andersen MK; thor Straten P; Guldberg P; Møller P; Zeuthen J; Ebbe Hansen N; Hou-Jensen K; Ralfkiaer E
    Leukemia; 1998 Aug; 12(8):1266-71. PubMed ID: 9697882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions.
    Kumanishi T; Zhang S; Ichikawa T; Endo S; Washiyama K
    Jpn J Cancer Res; 1996 Jul; 87(7):691-5. PubMed ID: 8698617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC).
    Eissa S; Ali-Labib R; Khalifa A
    Clin Chim Acta; 2000 Oct; 300(1-2):159-69. PubMed ID: 10958872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.